Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 1.18
- Piotroski Score 4.00
- Grade Buy
- Symbol (AMRX)
- Company Amneal Pharmaceuticals, Inc.
- Price $8.56
- Changes Percentage (0.18%)
- Change $0.02
- Day Low $8.47
- Day High $8.59
- Year High $8.95
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, promotion, distribution, and sale of branded pharmaceutical products with focus on central nervous system disorders, endocrinology, parasitic infections, and other therapeutic areas. It also offers Emverm, a chewable tablet for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; Rytary to treat Parkinson's disease; and Unithroid for the treatment of hypothyroidism. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. It is also involved in the wholesale distribution of bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names, as well as medical and surgical products; and packaging and wholesale distribution of pharmaceuticals and vitamins to its retail and institutional customers. The company sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. It operates in the United States, India, Ireland, and internationally. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/07/2024
- Fiscal Year End N/A
- Average Stock Price Target $8.00
- High Stock Price Target $12.00
- Low Stock Price Target $4.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.73
- Trailing P/E Ratio -9.25
- Forward P/E Ratio -9.25
- P/E Growth -9.25
- Net Income $-83,993,000
Income Statement
Quarterly
Annual
Latest News of AMRX
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Amneal Pharmaceuticals, Inc. (AMRX) Stock Price, News, Quote & History - Yahoo Finance
Amneal and Metsera have formed a strategic collaboration to create and distribute a range of advanced medications for obesity and metabolic diseases worldwide. The partnership aims to expedite the dev...
By Yahoo! Finance | 4 weeks ago -
Insider Sale at Amneal Pharmaceuticals Inc (AMRX) by Executive Vice President Andrew Boyer
Andrew Boyer, Executive VP of Amneal Pharmaceuticals Inc, sold 62,711 shares, now owning 256,670 shares. The company has seen insider selling recently, with no buys. With a market cap of $2....
By Yahoo! Finance | 2 months ago -
Insider Sale at Amneal Pharmaceuticals Inc (AMRX): Executive Vice President Nikita Shah Sells ...
Amneal Pharmaceuticals Inc has witnessed insider selling activity, with shares priced at $7.75. The company's market cap is $2.49 billion, but the stock is deemed significantly overvalued with an intr...
By Yahoo! Finance | 2 months ago
